top of page

USFDA Guidance: Content & Format of Labeling for Non-Prescription Drugs, Quantitative Labeling

Writer's picture: Sharan MuruganSharan Murugan

Earlier today on 8-September-2022, USFDA's Center for Drug Evaluation and Research, Office of New Drugs published two draft Labeling guidelines "Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products" and "Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products" which are open for comments.


Guidance: Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products


In this guideline, recommendations are made for the labeling of sodium, potassium, and phosphorus in human prescription and over-the-counter (OTC) medicines.


Its recommendations apply to orally ingested products as well as injectable medications that contain 5 mg or more sodium, potassium, or elemental phosphorus per maximum dose.

Guidance: Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products


The purpose of nonprescription drug product labels is to enable consumers to select appropriate and use the nonprescription drug product safely and effectively without medical supervision.


The statement of identity is one of the principal features of nonprescription drug product labeling and consists of the established name for the nonprescription drug product if one exists, followed by an accurate statement of the general pharmacological category or the principal intended action(s) of the drug product.


Consistent content and format of the statement of Identity and strength on the product’s principal display panel (PDP) may aid consumers in comparing nonprescription drug products and assist consumers in appropriate self-selection.


In this draft guidance, recommendations are given for the content and format of the statement of identity required on nonprescription human drugs and also provides recommendations on the inclusion of the drug product’s strength on the labeling.


As part of this draft guidance, manufacturers, packers, distributors, applicants, relabelers, and sponsors are advised to ensure that statements of identity and strength for human nonprescription drugs are consistent in content and format.






Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page